Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: A systematic review and meta-analysis of individual patient data

The Lancet Oncology

Volumn 16, Issue 16, 2015, Pages 1639-1650

  Meulendijks, Didier ^a   Henricks, Linda M ^a   Sonke, Gabe S ^a   Deenen, Maarten J ^a   Froehlich, Tanja K ^b   Amstutz, Ursula ^b   Largiadèr, Carlo R ^b   Jennings, Barbara A ^c   Marinaki, Anthony M ^d   Sanderson, Jeremy D ^d   Kleibl, Zdenek ^e   Kleiblova, Petra ^e   Schwab, Matthias ^f,g   Zanger, Ulrich M ^f,h   Palles, Claire ⁱ   Tomlinson, Ian ⁱ   Gross, Eva ^j   van Kuilenburg, André B P ^k   Punt, Cornelis J A ^k   Koopman, Miriam ^l   Beijnen, Jos H ^a,m   Cats, Annemieke ^a   Schellens, Jan H M ^a,m   more..

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^d ST THOMAS HOSPITAL   (United Kingdom)

^e CHARLES UNIVERSITY   (Czech Republic)

^f DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^g UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^h UNIVERSITY OF TÜBINGEN   (Germany)

ⁱ UNIVERSITY OF OXFORD   (United Kingdom)

^j TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^k UNIVERSITY OF AMSTERDAM   (Netherlands)

^l UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^m UTRECHT UNIVERSITY   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROPYRIMIDINE; FLUOROURACIL; UFT; ANTINEOPLASTIC ANTIMETABOLITE; TEGAFUR;

ADVERSE DRUG REACTION; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; COHORT ANALYSIS; DISEASE SEVERITY; DPYD GENE; DRUG SAFETY; GASTROINTESTINAL TOXICITY; GENETIC ASSOCIATION; GENETIC VARIABILITY; HAND FOOT SYNDROME; HETEROZYGOTE; HOMOZYGOTE; HUMAN; META ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; CHEMICALLY INDUCED; GASTROINTESTINAL DISEASES; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; HEMATOLOGIC DISEASES; METABOLISM; MULTIVARIATE ANALYSIS; NEOPLASMS; ODDS RATIO; PHARMACOGENETICS; PHENOTYPE; RISK ASSESSMENT; RISK FACTOR; SEVERITY OF ILLNESS INDEX;

ANTIMETABOLITES, ANTINEOPLASTIC; CAPECITABINE; DIHYDROURACIL DEHYDROGENASE (NADP); FLUOROURACIL; GASTROINTESTINAL DISEASES; GENETIC PREDISPOSITION TO DISEASE; HEMATOLOGIC DISEASES; HUMANS; MULTIVARIATE ANALYSIS; NEOPLASMS; ODDS RATIO; PHARMACOGENETICS; PHENOTYPE; POLYMORPHISM, GENETIC; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TEGAFUR;

EID: 84951335101     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)00286-7     Document Type: Article

References (47)

1. Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001, 19:2282-2292.
2. Tsalic M, Bar-Sela G, Beny A, Visel B, Haim N Severe toxicity related to the 5-fluorouracil/leucovorin combination (the Mayo Clinic regimen): a prospective study in colorectal cancer patients. Am J Clin Oncol 2003, 26:103-106.
3. Bajetta E, Procopio G, Celio L, et al. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol 2005, 23:2155-2161.
4. Lévy E, Piedbois P, Buyse M, et al. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol 1998, 16:3537-3541.
5. Van Kuilenburg ABP Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 2004, 40:939-950.
6. Amstutz U, Offer SM, Sistonen J, Joerger M, Diasio RB, Largiadèr CR Polymorphisms in MIR27A associated with early-onset toxicity in fluoropyrimidine-based chemotherapy. Clin Cancer Res 2015, 21:2038-2044.
7. Offer SM, Butterfield GL, Jerde CR, Fossum CC, Wegner NJ, Diasio RB microRNAs miR-27a and miR-27b directly regulate liver dihydropyrimidine dehydrogenase expression through two conserved binding sites. Mol Cancer Ther 2014, 13:742-751.
8. Zhang X, Li L, Fourie J, Davie JR, Guarcello V, Diasio RB The role of Sp1 and Sp3 in the constitutive DPYD gene expression. Biochim Biophys Acta 2006, 1759:247-256.
9. Schwab M, Zanger UM, Marx C, et al. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol 2008, 26:2131-2138.
10. Morel A, Boisdron-Celle M, Fey L, et al. Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance. Mol Cancer Ther 2006, 5:2895-2904.
11. Deenen MJ, Tol J, Burylo AM, et al. Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clin Cancer Res 2011, 17:3455-3468.
12. Lee AM, Shi Q, Pavey E, et al. DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147). J Natl Cancer Inst 2014, 106:1-12.
13. Rosmarin D, Palles C, Church D, et al. Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. J Clin Oncol 2014, 32:1031-1039.
14. Froehlich TK, Amstutz U, Aebi S, Joerger M, Largiadèr CR Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity. Int J Cancer 2015, 136:730-739.
15. Jennings BA, Loke YK, Skinner J, et al. Evaluating predictive pharmacogenetic signatures of adverse events in colorectal cancer patients treated with fluoropyrimidines. PLoS One 2013, 8:e78053.
16. Loganayagam A, Arenas Hernandez M, Corrigan A, et al. Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity. Br J Cancer 2013, 108:2505-2515.
17. Van Kuilenburg ABP, Haasjes J, Richel DJ, et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res 2000, 6:4705-4712.
18. Amstutz U, Froehlich TK, Largiadèr CR Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity. Pharmacogenomics 2011, 12:1321-1336.
19. Van Kuilenburg ABP, Dobritzsch D, Meinsma R, et al. Novel disease-causing mutations in the dihydropyrimidine dehydrogenase gene interpreted by analysis of the three-dimensional protein structure. Biochem J 2002, 364:157-163.
20. Vreken P, Van Kuilenburg AB, Meinsma R, et al. A point mutation in an invariant splice donor site leads to exon skipping in two unrelated Dutch patients with dihydropyrimidine dehydrogenase deficiency. J Inherit Metab Dis 1996, 19:645-654.
21. Terrazzino S, Cargnin S, Del Re M, Danesi R, Canonico PL, Genazzani AA DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis. Pharmacogenomics 2013, 14:1255-1272.
22. Van Kuilenburg ABP, Meinsma R, Zoetekouw L, Van Gennip AH High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity. Pharmacogenetics 2002, 12:555-558.
23. Deenen MJ, Meulendijks D, Cats A, et al. Upfront genotyping of DPYD*2A to individualize fluoropyrimidine therapy: a safety and cost analysis. J Clin Oncol (in press).
24. Johnson MR, Wang K, Diasio RB Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype. Clin Cancer Res 2002, 8:768-774.
25. Loganayagam A, Arenas-Hernandez M, Fairbanks L, Ross P, Sanderson JD, Marinaki AM The contribution of deleterious DPYD gene sequence variants to fluoropyrimidine toxicity in British cancer patients. Cancer Chemother Pharmacol 2010, 65:403-406.
26. Collie-Duguid ES, Etienne MC, Milano G, McLeod HL Known variant DPYD alleles do not explain DPD deficiency in cancer patients. Pharmacogenetics 2000, 10:217-223.
27. Offer SM, Wegner NJ, Fossum C, Wang K, Diasio RB Phenotypic profiling of DPYD variations relevant to 5-fluorouracil sensitivity using real-time cellular analysis and in vitro measurement of enzyme activity. Cancer Res 2013, 73:1958-1968.
28. Caudle KE, Thorn CF, Klein TE, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Clin Pharmacol Ther 2013, 94:640-645.
29. Amstutz U, Farese S, Aebi S, Largiadèr CR Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment. Pharmacogenomics 2009, 10:931-944.
30. Van Kuilenburg ABP, Meijer J, Mul ANPM, et al. Intragenic deletions and a deep intronic mutation affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity. Hum Genet 2010, 128:529-538.
31. Kleibl Z, Fidlerova J, Kleiblova P, et al. Influence of dihydropyrimidine dehydrogenase gene (DPYD) coding sequence variants on the development of fluoropyrimidine-related toxicity in patients with high-grade toxicity and patients with excellent tolerance of fluoropyrimidine-based chemotherapy. Neoplasma 2009, 56:303-316.
32. Pluim D, Jacobs BAW, Deenen MJ, et al. Improved pharmacodynamic assay for dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells. Bioanalysis 2015, 7:519-529.
33. Gross E, Busse B, Riemenschneider M, et al. Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patients. PLoS One 2008, 3:e4003.
34. Little J, Higgins JPT, Ioannidis JPA, et al. STrengthening the REporting of Genetic Association studies (STREGA): an extension of the STROBE Statement. Ann Intern Med 2009, 150:206-215.
35. Little J, Higgins JP The HuGENetTM HuGE Review Handbook, Version 1.0. Ottawa, Ontario, Canada: HuGENet Canada Coordinating Centre (accessed March 11, 2015). http://www.medicine.uottawa.ca/public-health-genomics/web/assets/documents/HuGE_Review_Handbook_V1_0.pdf.
36. Cox DR The continuity correction. Biometrika 1970, 57:217-219.
37. DerSimonian R, Laird N Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
38. Lau J, Ioannidis JP, Schmid CH Quantitative synthesis in systematic reviews. Ann Intern Med 1997, 127:820-826.
39. Stewart LA, Clarke M, Rovers M, et al. Preferred Reporting Items for a Systematic Review and Meta-analysis of Individual Participant Data. JAMA 2015, 313:1657.
40. Offer SM, Fossum CC, Wegner NJ, et al. Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity. Cancer Res 2014, 74:2545-2554.
41. Van Kuilenburg ABP, Häusler P, Schalhorn A, et al. Evaluation of 5-fluorouracil pharmacokinetics in cancer patients with a c.1905+1G>A mutation in DPYD by means of a Bayesian limited sampling strategy. Clin Pharmacokinet 2012, 51:163-174.
42. Diasio RB, Harris BE Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 1989, 16:215-237.
43. Henricks LM, Lunenburg CA, Meulendijks D, et al. Translating DPYD genotype into DPD phenotype: using the DPYD gene activity score. Pharmacogenomics 2015, 16:1-10.
44. Van Kuilenburg ABP, Meijer J, Mul ANPM, et al. Intragenic deletions and a deep intronic mutation affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity. Hum Genet 2010, 128:529-538.
45. Boisdron-Celle M, Remaud G, Traore S, et al. 5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency. Cancer Lett 2007, 249:271-282.
46. Meulendijks D, Jacobs BAW, Aliev A, et al. Increased risk of severe fluoropyrimidine-associated toxicity in patients carrying a G>C Substitution in the First 28-bp tandem repeat of the thymidylate synthase 2R Allele. Int J Cancer 2015, published online July 18. 10.1002/ijc.29694.
47. Begg CB, Berlin JA Publication bias: A problem in interpreting medical data. J R Stat Soc Ser A 1988, 151:419-463.